Share on StockTwits

Shares of Hologic (NASDAQ:HOLX) have earned an average rating of “Hold” from the twenty-one ratings firms that are presently covering the company, American Banking News.com reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $24.40.

HOLX has been the subject of a number of recent research reports. Analysts at Barrington Research downgraded shares of Hologic from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 5th. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hologic in a research note on Thursday, July 31st. They now have a $31.00 price target on the stock, up previously from $28.00. Finally, analysts at SunTrust reiterated a “r” rating on shares of Hologic in a research note on Thursday, July 31st. They now have a $18.00 price target on the stock, up previously from $15.00.

Shares of Hologic (NASDAQ:HOLX) opened at 25.63 on Thursday. Hologic has a one year low of $19.25 and a one year high of $26.75. The stock’s 50-day moving average is $25.54 and its 200-day moving average is $23.13. The company’s market cap is $7.119 billion.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.37 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.34 by $0.03. The company had revenue of $632.60 million for the quarter, compared to the consensus estimate of $621.89 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. Analysts expect that Hologic will post $1.45 EPS for the current fiscal year.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.